Indication
Mannitol infusion solution (Mannitol intravenous infusion, BP) can be
used in:
- The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established
- The reduction of elevated intraocular pressure when the pressure cannot be lowered by other means
- The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass
- Promoting the urinary excretion of toxic substances
- Bowel preparation. eg- Colorectal & Abdominal surgery
Dosage & Administration
The adult dose of Mannitol ranges from 50 to 100 g by IV infusion. The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50 ml/hr. Total dosage, concentration and the rate of administration depends on fluid requirement, urinary output and the
severity of the condition being treated.
Indications |
Adults |
Children |
|
50 to 100 g is |
2 g/kg body weight or |
|
administered at a rate |
60 g/square meter of |
Renal insufficiency |
adjusted to maintain a |
body surface area |
|
urine flow of at least 30 |
administered over a |
|
to 50 ml/hour. |
period of 2 to 6 hours. |
|
|
|
Cerebral edema, |
1.5 to 2 g/kg of body |
1 to 2 g/kg body weight |
elevated Intracranial |
weight administered |
or 30 to 60 g/square |
pressure, elevated |
over a period of 30 to |
meter of body surface |
intraocular pressure, |
60 minutes. |
area administered over |
Glaucoma |
|
a period of 30 to 60 |
|
|
minutes. |
Adjunctive therapy for |
50 to 200 g is |
2 g/kg body weight or |
removal of toxic |
administered at a rate |
60 g/square meter of |
substances |
adjust to maintain a |
body surface area. |
urine flow of at least 100 |
||
|
to 500 ml/hour. |
|
Precautions
Careful monitoring of rate of administration of Osmotic is necessary to avoid fluid and electrolytes imbalance and circulating overloading. The infusion should be discontinued if the patient develops signs of progressive renal dysfunction, heart failure or pulmonary congestion.
Mannitol should not be administered with whole blood.
Pregnancy:
Pregnancy category C. It is also not known whether Mannitol can cause fetal harm when administered to a pregnant woman or can affect
reproduction capacity. Mannitol should be given to a pregnant woman only if clearly needed.
Lactation:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised
when Mannitol is administered to a nursing woman.
